JP2001524824A - Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途 - Google Patents
Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途Info
- Publication number
- JP2001524824A JP2001524824A JP54436198A JP54436198A JP2001524824A JP 2001524824 A JP2001524824 A JP 2001524824A JP 54436198 A JP54436198 A JP 54436198A JP 54436198 A JP54436198 A JP 54436198A JP 2001524824 A JP2001524824 A JP 2001524824A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- crsp
- polypeptide
- nucleic acid
- accession number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84370497A | 1997-04-16 | 1997-04-16 | |
| US08/843,704 | 1997-04-16 | ||
| US84289897A | 1997-04-17 | 1997-04-17 | |
| US08/842,898 | 1997-04-17 | ||
| US7158998P | 1998-01-15 | 1998-01-15 | |
| US60/071,589 | 1998-01-15 | ||
| US980298A | 1998-01-20 | 1998-01-20 | |
| US09/009,802 | 1998-01-20 | ||
| PCT/US1998/007894 WO1998046755A1 (en) | 1997-04-16 | 1998-04-16 | Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005370262A Division JP2006166917A (ja) | 1997-04-16 | 2005-12-22 | Crspタンパク質、それらをコードする核酸分子およびその用途 |
| JP2009188614A Division JP2010011853A (ja) | 1997-04-16 | 2009-08-17 | Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001524824A true JP2001524824A (ja) | 2001-12-04 |
| JP2001524824A5 JP2001524824A5 (cg-RX-API-DMAC7.html) | 2006-07-20 |
Family
ID=27485904
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54436198A Pending JP2001524824A (ja) | 1997-04-16 | 1998-04-16 | Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途 |
| JP2005370262A Pending JP2006166917A (ja) | 1997-04-16 | 2005-12-22 | Crspタンパク質、それらをコードする核酸分子およびその用途 |
| JP2009188614A Pending JP2010011853A (ja) | 1997-04-16 | 2009-08-17 | Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途 |
| JP2010111163A Pending JP2010227110A (ja) | 1997-04-16 | 2010-05-13 | Crspタンパク質、それらをコードする核酸分子およびその用途 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005370262A Pending JP2006166917A (ja) | 1997-04-16 | 2005-12-22 | Crspタンパク質、それらをコードする核酸分子およびその用途 |
| JP2009188614A Pending JP2010011853A (ja) | 1997-04-16 | 2009-08-17 | Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途 |
| JP2010111163A Pending JP2010227110A (ja) | 1997-04-16 | 2010-05-13 | Crspタンパク質、それらをコードする核酸分子およびその用途 |
Country Status (11)
| Country | Link |
|---|---|
| EP (3) | EP2298899A3 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2001524824A (cg-RX-API-DMAC7.html) |
| AT (2) | ATE505543T1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU7137398A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2288430C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1107629T1 (cg-RX-API-DMAC7.html) |
| DE (2) | DE69842225D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0975755T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2285768T5 (cg-RX-API-DMAC7.html) |
| PT (1) | PT975755E (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998046755A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7057017B2 (en) | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| JP2001512012A (ja) * | 1997-08-01 | 2001-08-21 | ジェンセット | 精巣およびその他の組織で発現する分泌タンパク質の5’est |
| DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US7446181B2 (en) | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| US6344541B1 (en) * | 1998-09-25 | 2002-02-05 | Amgen Inc. | DKR polypeptides |
| JP5043254B2 (ja) * | 1998-10-26 | 2012-10-10 | ノボザイムス アクティーゼルスカブ | 糸状面細胞内の問題のdnaライブラリーの作製及びスクリーニング |
| CA2366062C (en) * | 1999-03-05 | 2014-06-17 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| US7115665B1 (en) | 2000-11-16 | 2006-10-03 | Onocozyme Pharma, Inc. | Inhibitors of endo-exonuclease activity for treating cancer |
| EP1234877B1 (en) * | 1999-11-19 | 2010-06-02 | Kumon, Hiromi | Cell proliferation inhibitory protein, polynucleotide, antisense polynucleotide to the polynucleotide, and cell proliferation inhibitors, cancer diagnostics, cancer remedies and compositions for gene therapy by using the same |
| ATE255229T1 (de) * | 2000-02-24 | 2003-12-15 | Oxford Glycosciences Uk Ltd | Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten |
| US7927597B2 (en) | 2001-04-10 | 2011-04-19 | Agensys, Inc. | Methods to inhibit cell growth |
| EP1573024A4 (en) | 2001-04-10 | 2007-08-29 | Agensys Inc | NUCLEIC ACIDS AND SUITABLE PROTEINS SUITABLE FOR THE TREATMENT AND EVIDENCE OF VARIOUS CANCER DISEASES |
| AU2002308557A1 (en) | 2001-05-01 | 2002-11-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| US20040038860A1 (en) | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| US7622553B2 (en) | 2003-11-17 | 2009-11-24 | Merck & Co., Inc. | Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof |
| US7473770B2 (en) | 2003-11-17 | 2009-01-06 | Merck & Co., Inc. | Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof |
| WO2005095448A2 (en) | 2004-03-23 | 2005-10-13 | Oscient Pharmaceuticals Corporation | Method of synthesizing and purifying dkk proteins and dkk proteins obtained thereby |
| ES2414460T3 (es) | 2004-08-04 | 2013-07-19 | Amgen Inc. | Anticuerpos para Dkk-1 |
| AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| US7465585B1 (en) * | 2006-04-10 | 2008-12-16 | The Burnham Institute | Compositions and methods for inhibiting cell migration |
| AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
| PH12023550779A1 (en) | 2020-09-28 | 2023-11-20 | Angitia Biomedicines Ltd | Anti-sclerostin constructs and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3751873T2 (de) | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| DE69034263D1 (de) | 1989-07-25 | 2009-04-02 | Cell Genesys Inc | Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992000968A1 (en) | 1990-07-10 | 1992-01-23 | Smithkline Beecham Corporation | Oxamides |
| WO1992009688A1 (en) | 1990-11-21 | 1992-06-11 | Massachusetts Institute Of Technology | MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| JP3537141B2 (ja) | 1992-10-30 | 2004-06-14 | ザ ゼネラル ホスピタル コーポレーション | 新種蛋白質分離のための相互作用を用いる補捉システム |
| ATE267877T1 (de) | 1993-01-07 | 2004-06-15 | Sequenom Inc | Dns - sequenzierung durch massenspektronomie |
| JP2879303B2 (ja) * | 1993-01-14 | 1999-04-05 | 佑 本庶 | cDNAライブラリーの作製方法、および新規なポリペプチドとそれをコードするDNA |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| WO1998027932A2 (en) * | 1996-12-20 | 1998-07-02 | Human Genome Sciences, Inc. | Cerebellum and embryo specific protein |
| DE19747418C1 (de) * | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
-
1998
- 1998-04-16 DE DE69842225T patent/DE69842225D1/de not_active Expired - Lifetime
- 1998-04-16 PT PT98918453T patent/PT975755E/pt unknown
- 1998-04-16 DK DK98918453T patent/DK0975755T3/da active
- 1998-04-16 AU AU71373/98A patent/AU7137398A/en not_active Abandoned
- 1998-04-16 ES ES98918453T patent/ES2285768T5/es not_active Expired - Lifetime
- 1998-04-16 DE DE69837085T patent/DE69837085T3/de not_active Expired - Lifetime
- 1998-04-16 AT AT06021943T patent/ATE505543T1/de not_active IP Right Cessation
- 1998-04-16 CA CA2288430A patent/CA2288430C/en not_active Expired - Lifetime
- 1998-04-16 EP EP10010403A patent/EP2298899A3/en not_active Withdrawn
- 1998-04-16 AT AT98918453T patent/ATE353964T1/de active
- 1998-04-16 JP JP54436198A patent/JP2001524824A/ja active Pending
- 1998-04-16 EP EP98918453A patent/EP0975755B2/en not_active Expired - Lifetime
- 1998-04-16 WO PCT/US1998/007894 patent/WO1998046755A1/en not_active Ceased
- 1998-04-16 EP EP06021943A patent/EP1852507B1/en not_active Expired - Lifetime
-
2005
- 2005-12-22 JP JP2005370262A patent/JP2006166917A/ja active Pending
-
2007
- 2007-05-14 CY CY20071100650T patent/CY1107629T1/el unknown
-
2009
- 2009-08-17 JP JP2009188614A patent/JP2010011853A/ja active Pending
- 2009-10-22 AU AU2009227915A patent/AU2009227915A1/en not_active Abandoned
-
2010
- 2010-05-13 JP JP2010111163A patent/JP2010227110A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2288430C (en) | 2013-04-09 |
| EP0975755A1 (en) | 2000-02-02 |
| AU7137398A (en) | 1998-11-11 |
| EP0975755B9 (en) | 2007-08-29 |
| CA2288430A1 (en) | 1998-10-22 |
| DE69837085D1 (de) | 2007-03-29 |
| EP1852507A1 (en) | 2007-11-07 |
| ATE353964T1 (de) | 2007-03-15 |
| ATE505543T1 (de) | 2011-04-15 |
| DE69837085T2 (de) | 2007-11-22 |
| EP0975755B1 (en) | 2007-02-14 |
| EP2298899A2 (en) | 2011-03-23 |
| JP2010011853A (ja) | 2010-01-21 |
| ES2285768T3 (es) | 2007-11-16 |
| PT975755E (pt) | 2007-06-26 |
| JP2006166917A (ja) | 2006-06-29 |
| DE69842225D1 (de) | 2011-05-26 |
| AU2009227915A1 (en) | 2009-11-12 |
| ES2285768T5 (es) | 2011-12-22 |
| DE69837085T3 (de) | 2012-01-12 |
| EP2298899A3 (en) | 2011-08-24 |
| EP1852507B1 (en) | 2011-04-13 |
| EP0975755B2 (en) | 2011-08-03 |
| DK0975755T3 (da) | 2007-06-11 |
| WO1998046755A1 (en) | 1998-10-22 |
| JP2010227110A (ja) | 2010-10-14 |
| CY1107629T1 (el) | 2013-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010011853A (ja) | Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途 | |
| US8754199B2 (en) | Tango 240 nucleic acids and uses thereof | |
| AU751396B2 (en) | Novel molecules of the Tango-77 related protein family and uses thereof | |
| US6623947B2 (en) | Human glucose-6-phosphatase molecules and uses thereof | |
| US6406884B1 (en) | Secreted proteins and uses thereof | |
| US6225085B1 (en) | LRSG protein and nucleic acid molecules and uses therefor | |
| CA2340796A1 (en) | Novel irap-bp polypeptide and nucleic acid molecules and uses therefor | |
| US6872811B1 (en) | HRPCa9 and HRPCa10 nucleic acids and polypeptides | |
| US6380382B1 (en) | Gene encoding a protein having diagnostic, preventive, therapeutic, and other uses | |
| JP2002514078A (ja) | Fthma−070関連蛋白質ファミリーおよびt85関連蛋白質ファミリーの新規分子ならびにそれらの使用 | |
| US6485921B1 (en) | UBCLP and uses thereof | |
| JP2002511480A (ja) | T129関連タンパク質ファミリーの新規分子およびその使用 | |
| AU2005248943B2 (en) | CRSP protein (Cysteine-Rich Secreted Proteins), nucleic acid molecules encoding them and uses therefor | |
| WO2000032746A2 (en) | Netrin-like and ependymin-like nucleic acids and polypeptides and uses thereof | |
| JP2002518061A (ja) | T110関連タンパク質ファミリーの新規な分子及びその使用 | |
| AU2010236081A1 (en) | CRSP protein (Cysteine-Rich Secreted Proteins), nucleic acid molecules encoding them and uses therefor | |
| AU2013200856A1 (en) | CRSP protein (Cysteine-Rich Secreted Proteins), nucleic acid molecules encoding them and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050407 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070821 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071116 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071221 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090414 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090817 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091203 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100225 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110914 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110922 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111014 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111020 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111117 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120724 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120730 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120824 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120829 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120924 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120927 |